A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma.
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Dose limited toxicity(DLT) observation in patient with r/r B cell Lymphoma
研究概览
简要总结
This is a phase 1/2, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) in patients with refractory or relapsed CD19 positive B cell Lymphoma.
详细描述
This is a phase 1/2, single-center, nonrandomized, open-label, dose-escalation and dose-expansion study to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A in patients with r/r CD19 positive B cell Lymphoma and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile. AIDS-related B-cell lymphoma were not excluded from this clinical trial.
Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine、cyclophosphamide and VP-16. At Day 0 of the Treatment Period, subjects will receive an intravenous (IV) infusion of ThisCART19A. All subjects are monitored during the treatment period through Day 42. All subjects who receive a dose of ThisCART19A will be followed up to 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years ≤ age ≤ 65 years.
- •Voluntarily sign a documented IRB-approved ICF prior to any screening procedure.
- •Patients with histologically confirmed B-cell NHL defined by the World Health Organization (WHO) 2016, including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma transferring to DLBCL, mantle cell lymphoma (MCL), follicular lymphoma 3B (FL-3B), original Mediastinal (thymus) large B-cell lymphoma, high-grade B-cell lymphoma and AIDS-associated B-cell lymphoma.
- •Prior therapy must have included: Anti-CD20 monoclonal antibody and Anthracycline containing chemotherapy regimen.
- •Had available evaluation lesion.
- •ECOG(Eastern Cooperative Oncology Group) ≤ 2 or Karnofsky ≥ 60%.
- •Serum creatinine≤1.5×ULN or creatinine clearance>30 mL/min/1.73 m
- •Alanine aminotransferase(ALT)≤5×ULN(Upper limit of normal) and total bilirubin(TBIL)<2.0 mg/dL(for patients with Gilbert heald diseases, live involvement and taking atazanavir or indinavir, TBIL<3.0 mg/dL can be enrolled.)
- •Left ventricular ejection fraction(LVEF)≥40%
- •Absolute neutrophile counts≥1000/mm3
- •Thrombocyte≥30000/mm3
- •Total bilirubin(TBIL) ≤ 2.0 mg/dL
- •Confirmed Cluster of differentiation(CD)19 positive by biopsy for the patients who received CD19 target therapy before.
- •Pregnancy tests for women of childbearing age shall be negative; Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.
- •AIDS Related B Cell Lymphoma :HIV virus loading < 200 copy/ml and CD4+T cell counts >200 cells/mm3 within 4 weeks before screening.
- •Patients with TBIL≤ 1.5 mg/dL, Aspartate aminotransferase(AST) and ALT ≤ 3×ULN, and hepatitis B virus(HBV) DNA <2000 IU/ml can be enrolled for HBV positive patients(defined as hepatitis B virus surface antigen(HBsAg) positive and hepatitis B core(HBc)-total positive ) and hepatitis C virus(HCV) positive patients(defined as HCV antibody positive) . Patients with cirrhosis are excluded.
- •Hepatitis B core antibody(HBcAb) positive patients enrolled in this trial have to taking anti-HBV drugs during the whole research.
排除标准
- •Known for allergic to the preconditioning measures.
- •Uncontrollable bacterial, fungal, viral infection before enrollment.
- •Patients with pulmonary embolism within 3 months prior enrollment.
- •Intolerable serious cardiovascular and cerebrovascular diseases and hereditary diseases.
- •Imaging confirmed the presence of central nervous system involvement(including primary and secondary) and rapid progressing diseases.
- •Receive allogeneic hematopoietic stem cell transplantation less than 100 days.
- •Systemic steroid use (e.g., prednisone ≥20mg) within 3 days prior to screening. iIntermittent use of topical, inhaled or intranasal steroids recently or currently. Or systemic disease requiring long-term use of immunosuppression drugs.
- •Excluded the patients received Influenza vaccinations within 2 weeks prior to lymphodepletion (Received Severe Acute Respiratory Syndrome-Corona virus disease(SARS-COV)19 vaccines could be included. Received inactivated, live/non-live adjuvant vaccines could be enrolled).
- •Excluded women who are in pregnant or lactating, and female subjects or partners who plan to be pregnant within 1 year after infusion. Male subjects planning pregnancy within 1 year after infusion should be excluded.
研究组 & 干预措施
ThisCART19A cells infusion
In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used to treat patients with r/r B cell Lymphoma.
干预措施: ThisCART19A (Drug)
ThisCART19A cells infusion
In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used to treat patients with r/r B cell Lymphoma.
干预措施: Fludarabine (Drug)
ThisCART19A cells infusion
In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used to treat patients with r/r B cell Lymphoma.
干预措施: Cyclophosphamide (Drug)
ThisCART19A cells infusion
In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used to treat patients with r/r B cell Lymphoma.
干预措施: Etoposide (Drug)
结局指标
主要结局
Dose limited toxicity(DLT) observation in patient with r/r B cell Lymphoma
时间窗: 28 days
DLT was defined as CAR T cells-related events with onset within first 28 days following infusion.
The incidence of all grade TEAEs and ≥3 grade TEAEs
时间窗: Up to 2 years after ThisCART19A infusion
Incidence of treatment-emergent adverse events (TEAEs) and ≥3 grade TEAEs
Progress-free survival (PFS)
时间窗: Up to 2 years after ThisCART19A infusion
PFS is defined as the time from the ThisCART19A infusion date to the date of disease progression assessed by investigators and based on the Lugano 2014 assessment criterion, or death any cause.
Objective Response Rate
时间窗: Up to 2 years after ThisCART19A infusion
the incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as best response to treatment.
Duration of response (DOR)
时间窗: Up to 2 years after ThisCART19A infusion
DOR is defined as the date of their first CR or PR (which is subsequently confirmed) to PD assessed by investigators and based on the Lugano 2014 assessment criterion for r/r B cell Lymphoma, or death regardless of cause.
次要结局
- TTR (Time to response)(Up to 2 years after ThisCART19A infusion)
- OS (Overall survival)(Up to 2 years after lymphodepletion)